Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

PURPOSE: To compare the visual and anatomic outcomes of aflibercept versus ranibizumab as a second line treatment for persistent diabetic macular edema (DME) after initial bevacizumab injections. METHODS: In this retrospective cohort study, patients with center-involved DME of ≥ 300 μm thickness aft...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Ophthalmol
Egile Nagusiak: Alsaedi, Nasser G, Alselaimy, Ruba M, Alshamrani, Abdulaziz A, AlAjmi, Muhammed, Khandekar, Rajiv, Al-Dhibi, Hassan, Al-Abdullah, Abdulelah A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove 2021
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8286127/
https://ncbi.nlm.nih.gov/pubmed/34285463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S316271
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak